|
FBXW2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.5701999941179E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.69779999953579E-07 |
| Normal-vs-Stage2 |
1.377650E-03 |
| Normal-vs-Stage3 |
1.20690000215973E-08 |
| Normal-vs-Stage4 |
1.71619995992245E-09 |
| Stage1-vs-Stage2 |
7.266200E-01 |
| Stage1-vs-Stage3 |
6.522400E-02 |
| Stage1-vs-Stage4 |
9.579600E-03 |
| Stage2-vs-Stage3 |
1.431830E-01 |
| Stage2-vs-Stage4 |
3.428100E-02 |
| Stage3-vs-Stage4 |
2.795800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.52040002599341E-09 |
| Normal-vs-AfricanAmerican |
2.541600E-03 |
| Normal-vs-Asian |
5.91799999999365E-05 |
| Caucasian-vs-AfricanAmerican |
4.843200E-01 |
| Caucasian-vs-Asian |
5.731200E-01 |
| AfricanAmerican-vs-Asian |
7.947600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.86300000163342E-08 |
| Normal-vs-Female |
3.69179999903935E-08 |
| Male-vs-Female |
5.440600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.08459999995192E-06 |
| Normal-vs-Age(41-60Yrs) |
1.00469999986252E-07 |
| Normal-vs-Age(61-80Yrs) |
1.06719999504179E-08 |
| Normal-vs-Age(81-100Yrs) |
2.339100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.698800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.439700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.768600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.319600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.269800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.478800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.312300E-02 |
| Classical-VS-Follicular |
7.602200E-01 |
| Classical-VS-Other |
1.450950E-01 |
| Classical-VS-Normal |
1.62049999974379E-07 |
| Tall-VS-Follicular |
8.235500E-02 |
| Tall-VS-Other |
7.068600E-01 |
| Tall-VS-Normal |
2.83430000025398E-07 |
| Follicular-VS-Other |
2.874400E-01 |
| Follicular-VS-Normal |
7.79260000000059E-05 |
| Other-VS-Normal |
1.422710E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.2270999994477E-07 |
| Normal-vs-N1 |
1.37029999569549E-08 |
| N0-vs-N1 |
3.388000E-02 |
|
|
